Autoimmune Pulmonary Alveolar Proteinosis with Suspected Exacerbation after Osimertinib Administration for Lung Cancer

Intern Med. 2023 Apr 15;62(8):1203-1206. doi: 10.2169/internalmedicine.0256-22. Epub 2022 Sep 6.

Abstract

A 46-year-old woman with lung cancer who received chemotherapy was admitted to our hospital for lower-lobe bilateral ground-glass opacity (GGO). GGO developed after the lung cancer diagnosis, deteriorated after the initiation of osimertinib, and incompletely decreased after interrupting osimertinib; therefore, flexible bronchoscopy was performed. Transbronchial lung biopsy histology and anti-granulocyte/macrophage colony-stimulating factor autoantibody positivity revealed autoimmune pulmonary alveolar proteinosis (aPAP) that did not require treatment. This rare case of aPAP comorbid with lung cancer suggested that using PAP findings to differentiate from drug-induced lung injury or lymphangitis is difficult and that osimertinib was suspected to exacerbate aPAP.

Keywords: anti-granulocyte/macrophage colony-stimulating factor autoantibody; lung cancer; osimertinib; pulmonary alveolar proteinosis; tyrosine kinase inhibitor.

Publication types

  • Case Reports

MeSH terms

  • Autoimmune Diseases* / diagnosis
  • Female
  • Humans
  • Lung / pathology
  • Lung Neoplasms* / drug therapy
  • Lung Neoplasms* / pathology
  • Middle Aged
  • Pulmonary Alveolar Proteinosis* / chemically induced
  • Pulmonary Alveolar Proteinosis* / diagnostic imaging

Substances

  • osimertinib

Supplementary concepts

  • Pulmonary Alveolar Proteinosis, Acquired